US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jun 12, 2019 (7 years ago)

DACARBAZINE 680 MG in 250 ml NS

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

What was recalled

DACARBAZINE 680 MG in 250 ml NS; DACARBAZINE 675 MG in 250 ml NS, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233

Recalling firm
Infusion Options, Inc.
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1763-2019

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Dacarbazine recalls

See all
Class II · Moderate risk Terminated

Dacarbazine for Injection USP

Reason Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Teva Pharmaceuticals USA NDC 0703-5075-01 D-0271-2021
Class III · Low risk Terminated

Dacarbazine

Reason Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.

Hospira Inc. NDC 61703-327-22 D-0313-2015
Class II · Moderate risk Terminated

Dacarbazine active pharmaceutical ingredient packaged in varying…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-609-2015